Compare Eli Lilly And Co (LLY) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance

Eli Lilly (LLY) trades at $1,175.15, down 0.33% on the day, with a bullish technical signal and strong fundamental momentum. Revenue surged to $65.18B in 2025, with net income reaching $20.64B, and the company has beaten earnings estimates for three consecutive quarters. Recent news includes a lawsuit from Novo Nordisk over weight-loss drug advertising, but analyst sentiment remains overwhelmingly positive with a $1,380 consensus price target.

Outlook is supported by robust earnings growth and high profitability margins, but risks include competitive pressures and elevated valuation multiples. The stock's current price is near key resistance at $1,174, with institutional buying activity indicating continued confidence in Lilly's growth trajectory in the pharmaceutical sector.

TSLL is trading at $10.72, down 5.84% over the past day, with a bearish technical signal from moving averages and neutral oscillators. Key support lies at $10 and resistance at $11. The company has announced a future dividend of $0.10 per share scheduled for June 30, 2026. Recent news highlights focus on Tesla's upcoming earnings and related ETF movements, which may influence TSLL's performance given its thematic exposure.

The outlook for TSLL is cautious due to bearish technical indicators and reliance on Tesla's earnings catalyst. Investment opportunities hinge on positive earnings surprises from Tesla boosting the ETF, while risks include continued technical weakness and broader market volatility affecting leveraged ETF performance.